Objective:To explore influence of large dose γ globulin on myocardial cardiac myosin heavy chain (CM‐HC) own IgG antibody titer and therapeutic effect in patients with dilated cardiomyopathy (DCM) heart failure (HF) .Methods :A total of 160 DCM + HF patients hospitalized in our department of cardiology from Mar 2011 to May 2014 were selected .According to random number table ,they were randomly and equally divided into routine treatment group (n=80 ,RT group) and γglobulin group (n=80 ,received large dose γ globulin therapy based on RT group) .Cardiac function indexes ,IgG antibody titer and serum levels of cTnT and cTnI were observed and com‐pared between two groups before and after treatment .Results:Compared with before treatment after six -month treatment ,there were significant reductions in LVEDd [ (67.50 ± 5.50) mm vs .(56.50 ± 2.50) mm] and LVESd [ (55.50 ± 6.80) mm vs .(43.50 ± 2.30) mm] ,and significant rise in LVEF [ (33.50 ± 3.50)% vs .(53.50 ± 8.50)% ] in γglobulin group ,and only LVEF significantly rose [ (32.80 ± 4.20)% vs .(41.50 ± 5.50)% ] in RT group , P< 0.05 all;compared with RT group after six -month treatment , there were significant reductions in LVEDd [ (63.50 ± 2.50) mm vs .(56.50 ± 2.50) mm] and LVESd [ (51.60 ± 4.80) mm vs .(43.50 ± 2.30) mm] , and significant rise in LVEF in γglobulin group , P<0.05 all .On one ,three ,five and six months after treatment , IgG antibody titer significantly reduced in γglobulin group and they were significantly lower than those of RT group (P<0.05 all) .After six -month treatment ,cTnT and cTnI levels of both groups were significantly lower than those of before treatment ( P< 0.05 all ) , compared with RT group , there were significant reductions in cTnT [ (0.55 ± 0.10)μg/L vs .(0.26 ± 0.02)μg/L] and cTnI levels [ (1.20 ± 0.40)μg/L vs .(0.60 ± 0.10)μg/L] in γglobulin group , P<0.05 both .Conclusion:Large dose γglobulin can significantly improve myocardial function ,re‐duce myocardial CMHC own IgG antibody level and serum concentrations of cTnT and cTnI in DCM + HF pa‐tients ,so it’ s worth extending .%目的：探究大剂量丙种球蛋白对扩张型心肌病（DCM）心力衰竭患者心肌肌凝蛋白重链（CMHC）自身免疫球蛋白G （IgG ）抗体滴度和临床疗效的影响。方法：选择2011年3月～2014年5月我院心内科收治的DCM心力衰竭患者160例。按照随机数字表法，患者被随机均分分为常规治疗组（80例）和丙种球蛋白组（80例，在常规治疗组基础上接受大剂量丙种球蛋白治疗）。观察比较两组患者治疗前后的心功能指标， IgG抗体滴度以及血清心肌肌钙蛋白 T （cTnT ）和 cTnI水平。结果：与治疗前比较，治疗6个月后丙种球蛋白组左室舒张末期内径[LVEDd ，（67.50±5.50） mm比（56.50±2.50） mm]和左室收缩末期内径[LVESd ，（55.50±6.80） mm比（43.50±2.30） mm]显著降低，左室射血分数[LVEF ，（33.50±3.50）％ 比（53.50±8.50）％ ]显著升高，而常规治疗组仅LVEF [（32.80±4.20）％ 比（41.50±5.50）％ ]显著升高， P均＜0.05；与常规治疗组比较，治疗6个月后丙种球蛋白组的LVEDd [（63.50±2.50） mm比（56.50±2.50） mm]和LVESd [（51.60±4.80） mm比（43.50±2.30） mm]显著降低，LVEF显著升高，P均＜0.05。治疗1、3、5和6个月后，丙种球蛋白组IgG抗体滴度显著降低，且均显著低于同期常规治疗组的（P均＜0.05）。治疗6个月后两组cTnT和cTnI水平均较治疗前显著减低（P均＜0.05），且与常规治疗组比较，丙种球蛋白组cTnT [（0.55±0.10）μg／L比（0.26±0.02）μg／L]和cTnI水平 [（1.20±0.40）μg／L比（0.60±0.10）μg／L]下降更显著（P均＜0.05）。结论：大剂量丙种球蛋白治疗扩张型心肌病心力衰竭患者，能够显著改善患者的心肌功能，明显降低心肌肌凝蛋白重链自身 IgG抗体水平，显著降低血清肌钙蛋白T和I的含量，值得在临床上推广。
展开▼
